Are these Earning-Related Moves Fundamentally Warranted? Trulia Inc (TRLA) and More

Stock Falls With Bad Earnings Already Priced

Mining company Cliffs Natural Resources Inc (NYSE:CLF) fell 13.75% in early trading to add to its 50% loss over the last year. The company actually beat expectations, but revenue losses continue to scare investors. Then, there was the company’s decision to cut its dividend by 76% and announce a public offering! There aren’t too many positives to draw upon this quarter; however, at what price is bad earnings already priced into a stock?

The company’s valuation had fallen 50% in the last year alone, yet its revenue for the quarter only declined 4% compared to a full-year loss of 11%. I view these facts as positive, revenue may be finding a bottom and with a P/E ratio under 6 and a price/sales under 1 the stock is cheap. I am not sure I’d try to catch the falling knife on Wednesday, but after the panic subsides then we could see a nice rebound.

Conclusion

A stock’s performance after earnings does not necessarily mean that a company posted a good, or a bad, quarter. Too often we associate stock performance with fundamental performance, yet it’s the inconsistencies between these two factors that create value. The ability to identify these inconsistencies is a psychological behavior-changing skill that very few investors are able to perfect. In the past, I have talked about this subject in great detail, and have taught investors how to change these tendencies to return large gains. My advice is to become a smart investor, by learning how to read quarterly reports and assess the quarter without looking at stock performance. Then, if a stock trades incorrectly you are better able to capitalize on the value.

The article Are these Earning-Related Moves Fundamentally Warranted? originally appeared on Fool.com and is written by Brian Nichols.

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Biotech Insider Alert - $5 Stock To Hit $40

$200 Million Dollar Healthcare Hedge Fund's #1 Best Idea Right Now

The best healthcare hedge fund out there right now is one of the largest shareholders in this biotech stock. The fund returned more than 20% in each of the last 2 years with a virtually fully hedged portfolio, and it's sending out a BUY signal on this biotech stock. Get your FREE REPORT today (retail value of $300)

This is a FREE report from Insider Monkey. Credit Card is NOT required.
X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 129% in 2.5 years!! Wondering How?

Download a complete edition of our newsletter for free!